Breaking News Instant updates and real-time market news.

BIIB

Biogen

$235.61

4.05 (1.75%)

, NVTA

Invitae

$25.78

0.6 (2.38%)

07:32
08/20/19
08/20
07:32
08/20/19
07:32

Biogen, Invitae announce availability of SMA STAT test

Biogen (BIIB) and Invitae Corporation (NVTA) announced that SMA STAT, a new, rapid-turnaround genetic test for spinal muscular atrophy, will be offered at no charge to individuals in the U.S. as part of the SMA Identified program. The SMA STAT test reduces the time needed for genetic testing to help confirm a definitive diagnosis of SMA from 21 to four days, enabling individuals and physicians to plan and begin treatment earlier for what is often a life-threatening disease. Clinical studies have demonstrated that early diagnosis and treatment of SMA may prevent the development of severe symptoms, improve motor function and slow the progression of the disease. A preliminary diagnosis of SMA is typically made through a physician assessment after an individual has developed symptoms, although a diagnosis can also be made through newborn screening. Genetic testing confirms an SMA diagnosis and provides more information that can be used to help guide treatment and care planning decisions. The SMA STAT test detects deletions in the SMN1 gene and assesses copy number of the SMN2 gene, both essential pieces of information for diagnosing and treating SMA. The presence of a greater number of SMN2 copies is generally associated with less severe but still life altering forms of the disease.

BIIB

Biogen

$235.61

4.05 (1.75%)

NVTA

Invitae

$25.78

0.6 (2.38%)

  • 09

    Sep

BIIB Biogen
$235.61

4.05 (1.75%)

07/26/19
PIPR
07/26/19
NO CHANGE
PIPR
Neutral
AbbVie trial discontinuation adds risk to Biogen pipeline, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond is "incrementally cautious" on Biogen (BIIB) shares after AbbVie (ABBV) announced its anti-tau antibody Phase 2 trial in progressive supranuclear palsy was discontinued for futility. Biogen's anti-tau antibody BIIB092 is currently in a Phase 2 progressive supranuclear palsy trial with a readout anticipated by year-end 2019, Raymond tells investors in a research note. While the analyst does not model this opportunity, he points out that Biogen management, as recently as May, highlighted BIIB092 in PSP as a key event. Raymond thinks AbbVie's failure "adds an additional element of risk" to BIIB092 and he remains Neutral on Biogen shares. The stock in morning trading is down 1.5% to $234.63.
07/30/19
JPMS
07/30/19
NO CHANGE
JPMS
Overweight
Alkermes, Biogen data a positive, but questions remain, says JPMorgan
JPMorgan analyst Cory Kasimov views the data this morning from Alkermes (ALKS) and Biogen (BIIB) as an incremental positive but he believes commercial questions remain for Vumerity. The analyst has an Overweight rating on Alkermes and Neutral rating on Biogen. How doctors will view this dataset and how aggressive Biogen will be in launching Vumerity in the face of questions regarding Tecfidera's ultimate runway are the next key questions, Kasimov tells investors in a research note. However, he calls this morning's news a "good-to-see outcome."
07/30/19
PIPR
07/30/19
NO CHANGE
PIPR
Neutral
Biogen investors may be disappointed by Vumerity update, says Piper Jaffray
After Biogen reported top-line results from the Phase 3 EVOLVE-MS-2 study comparing Vumerity head-to-head versus Tecfidera, Piper Jaffray analyst Christopher Raymond said he thinks investors may be disappointed after "digging into" the update. Vumerity looks "decidedly better" than Tecfidera on flushing, diarrhea, nausea and AE-related discontinuations, but the drug showed "meaningfully worse" tolerability than previously seen, according to Raymond, who also said that adverse events now seem more in-line with what had been seen in Tecfidera's much larger pivotal trials. Given that he continues to see increased competitive pressure on Tecfidera and Tysabri, he remains comfortable on the sidelines with respect to Biogen shares and keeps a Neutral rating on the stock.
07/30/19
PIPR
07/30/19
NO CHANGE
PIPR
Neutral
Piper says Alkermes scores 'back-to-back wins' with settlement, Biogen data
Piper Jaffray analyst Danielle Brill said Alkermes (ALKS) has scored "back-to-back wins" with its announcement yesterday that it settled the ongoing Vivitrol patent dispute with Amneal (AMRX) and the news this morning that BIIB098 showed a statistically significant improvement on GI tolerability versus Tecfidera in a head-to-head Phase 3 trial. She still questions how meaningful the improvement in GI tolerability actually is, but thinks the drug may become a priority for partner Biogen (BIIB), Brill tells investors. The analyst, who views the news of the last two days as net positive for Alkermes, maintains her concerns about long-term value creation and the company's "dry pipeline," she said. Brill keeps a Neutral rating on Alkermes shares.
NVTA Invitae
$25.78

0.6 (2.38%)

03/04/19
03/04/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. MannKind (MNKD) initiated with an Outperform at SVB Leerink. 2. Invitae (NVTA) initiated with a Buy at Chardan. 3. Immunomedics (IMMU) initiated with a Buy at H.C. Wainwright. 4. Canopy Growth (CGC) initiated with a Neutral at Melius Research. 5. Alector (ALEC) initiated with an Overweight at Morgan Stanley and Barclays, an Outperform at SVB Leerink and Cowen, as well as a Buy at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
04/08/19
OPCO
04/08/19
NO CHANGE
Target $30
OPCO
Outperform
Invitae price target raised to $30 from $21 at Oppenheimer
Oppenheimer analyst Kevin DeGeeter raised his price target for Invitae to $30 from $21 based on improved long-term competitive positioning for the company's patient-initiated testing given data presented at the ACMG meeting demonstrating poor performance for a leading DTC genetic test and potential consolidation in DTC market as industry matures and economies of scale, quality/clinical data and regulatory oversight drive market share. The analyst reiterates an Outperform rating on the shares.
04/23/19
BNCH
04/23/19
NO CHANGE
BNCH
UnitedHealth preferred lab launch a long-term plus for Invitae, says Benchmark
Benchmark analyst Bruce Jackson noted that UnitedHealthcare (UNH) plans to launch a Preferred Laboratory Network to include Invitae (NVTA), which he views as a long-term positive for the latter and "another building block for Invitae's strategy to make genetic testing more widely available and more easily reimbursed." Other labs named to the preferred network include LabCorp (LH), Quest Diagnostics (DGX), and BioReference and GeneDx, which are both part of Opko (OPK), the analyst noted. UnitedHealthcare's current network includes NeoGenomics (NEO) and he doesn't anticipate any impact to NeoGenomics from the preferred network launch, added Jackson.
07/12/19
BNCH
07/12/19
NO CHANGE
Target $26
BNCH
Buy
Invitae price target raised to $26 after Jungla deal announcement at Benchmark
Benchmark analyst Bruce Jackson raised his price target on Invitae shares to $26 from $22 following the company's announcement of a deal to acquire privately-held Jungla for $50M plus potential milestone payments. The analyst, who said the deal adds to Invitae's hereditary cancer testing capabilities, keeps a Buy rating on the stock.

TODAY'S FREE FLY STORIES

GDOT

Green Dot

$27.48

0.19 (0.70%)

14:55
09/19/19
09/19
14:55
09/19/19
14:55
Conference/Events
Green Dot participates in a conference call with SunTrust »

Conference call with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

STXS

Stereotaxis

$4.07

-0.27 (-6.22%)

14:52
09/19/19
09/19
14:52
09/19/19
14:52
Syndicate
Breaking Syndicate news story on Stereotaxis »

Stereotaxis files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

M

Macy's

$15.77

-0.52 (-3.19%)

14:43
09/19/19
09/19
14:43
09/19/19
14:43
Periodicals
Macy's to offer free same-day delivery for a limited time, Retail Dive reports »

Macy's has announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

TTEC

TTEC Holdings

$49.79

0.24 (0.48%)

14:41
09/19/19
09/19
14:41
09/19/19
14:41
Initiation
TTEC Holdings initiated  »

TTEC Holdings initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

IRBT

iRobot

$61.87

-0.58 (-0.93%)

14:35
09/19/19
09/19
14:35
09/19/19
14:35
Options
iRobot put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

CNNE

Cannae Holdings

$26.72

-0.02 (-0.07%)

14:32
09/19/19
09/19
14:32
09/19/19
14:32
Hot Stocks
Cannae Holdings announces three-year, 5M share repurchase program »

Cannae Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 13

    Nov

TSL

Trina Solar

$0.00

(0.00%)

, CSIQ

Canadian Solar

$22.24

0.56 (2.58%)

14:28
09/19/19
09/19
14:28
09/19/19
14:28
Periodicals
Solar and wind power 'so cheap they're outgrowing subsidies,' Bloomberg says »

According to…

TSL

Trina Solar

$0.00

(0.00%)

CSIQ

Canadian Solar

$22.24

0.56 (2.58%)

SPWR

SunPower

$15.20

0.775 (5.37%)

FSLR

First Solar

$67.32

1.55 (2.36%)

JASO

JA Solar

$0.00

(0.00%)

YGE

Yingli Green Energy

$0.00

(0.00%)

SUNEQ

SunEdison

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:20
09/19/19
09/19
14:20
09/19/19
14:20
General news
Treasury Action: Treasuries are holding modest gains »

Treasury Action:…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
09/19/19
09/19
14:17
09/19/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
09/19/19
09/19
14:16
09/19/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOGM

LogMeln

$68.03

-0.63 (-0.92%)

14:11
09/19/19
09/19
14:11
09/19/19
14:11
Periodicals
Breaking Periodicals news story on LogMeln »

LogMeln turns positive,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BSX

Boston Scientific

$42.86

-0.06 (-0.14%)

, VAR

Varian Medical

$115.91

-1.54 (-1.31%)

14:11
09/19/19
09/19
14:11
09/19/19
14:11
Hot Stocks
Boston Scientific required to divest certain assets to Varian regarding BTG buy »

Medical device company…

BSX

Boston Scientific

$42.86

-0.06 (-0.14%)

VAR

Varian Medical

$115.91

-1.54 (-1.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 23

    Oct

  • 13

    Nov

LOGM

LogMeln

$68.03

-0.63 (-0.92%)

14:10
09/19/19
09/19
14:10
09/19/19
14:10
Periodicals
Dealreporter says LogMeln having informal talks on selling parts, Bloomberg says »

Bloomberg cites…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$9.47

0.085 (0.91%)

14:06
09/19/19
09/19
14:06
09/19/19
14:06
Periodicals
Nelson Peltz says GE CEO Larry Culp is 'fantastic,' Reuters reports »

Trian Partners'…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

HIIQ

Health Insurance Innovations

$22.37

1.59 (7.65%)

14:05
09/19/19
09/19
14:05
09/19/19
14:05
Options
Health Insurance Innovations call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 02

    Oct

STX

Seagate

$52.92

-3.82 (-6.73%)

13:59
09/19/19
09/19
13:59
09/19/19
13:59
Recommendations
Seagate analyst commentary  »

Seagate price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

SPY

SPDR S&P 500 ETF Trust

$301.58

0.48 (0.16%)

, SPX

S&P 500

$0.00

(0.00%)

13:51
09/19/19
09/19
13:51
09/19/19
13:51
General news
Global Times' Xijin says China 'not as anxious to reach a deal' as U.S. thought »

Hu Xijin, editor-in-chief…

SPY

SPDR S&P 500 ETF Trust

$301.58

0.48 (0.16%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AFL

Aflac

$52.71

0.11 (0.21%)

13:48
09/19/19
09/19
13:48
09/19/19
13:48
Conference/Events
Aflac to host analyst briefing »

Financial Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 27

    Sep

ZYNE

Zynerba

$8.19

-0.65 (-7.35%)

, GWPH

GW Pharmaceuticals

$134.90

-0.73 (-0.54%)

13:47
09/19/19
09/19
13:47
09/19/19
13:47
Recommendations
Zynerba, GW Pharmaceuticals analyst commentary  »

Zynerba selloff on…

ZYNE

Zynerba

$8.19

-0.65 (-7.35%)

GWPH

GW Pharmaceuticals

$134.90

-0.73 (-0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 02

    Oct

13:40
09/19/19
09/19
13:40
09/19/19
13:40
General news
Treasury's $12 B 10-yer TIPS reopening was ok »

Treasury's $12 B…

WE

We Company

$0.00

(0.00%)

13:38
09/19/19
09/19
13:38
09/19/19
13:38
Periodicals
WeWork leaves sensitive documents exposed via 'weak' Wi-Fi, CNet reports »

WeWork's weak Wi-Fi…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENS

EnerSys

$64.00

0.24 (0.38%)

13:34
09/19/19
09/19
13:34
09/19/19
13:34
Hot Stocks
EnerSys reports fire at Richmond, Kentucky production facility »

EnerSys reports that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 02

    Oct

  • 13

    Nov

  • 14

    Nov

EE

El Paso Electric

$66.83

0.13 (0.19%)

, JPM

JPMorgan

$120.02

0.25 (0.21%)

13:29
09/19/19
09/19
13:29
09/19/19
13:29
Hot Stocks
El Paso Electric investors approve deal to be acquired by IIF »

El Paso Electric Company…

EE

El Paso Electric

$66.83

0.13 (0.19%)

JPM

JPMorgan

$120.02

0.25 (0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 15

    Oct

  • 27

    Oct

ADVM

Adverum Biotechnologies

$6.47

0.28 (4.52%)

13:25
09/19/19
09/19
13:25
09/19/19
13:25
Options
Adverum Biotechnologies call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Oct

13:25
09/19/19
09/19
13:25
09/19/19
13:25
General news
FX Action: USD-JPY »

FX Action: USD-JPY has…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.